These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25420520)

  • 1. ERG induces taxane resistance in castration-resistant prostate cancer.
    Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
    Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
    Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
    Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
    Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
    Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
    de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
    Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer.
    Kroon J; Kooijman S; Cho NJ; Storm G; van der Pluijm G
    Trends Pharmacol Sci; 2016 Jun; 37(6):451-462. PubMed ID: 27068431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
    Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
    Schutz FA; Buzaid AC; Sartor O
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the
    Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
    Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells.
    Eskra JN; Schlicht MJ; Bosland MC
    Sci Rep; 2019 Mar; 9(1):4367. PubMed ID: 30867440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.
    Dijkstra S; Leyten GH; Jannink SA; de Jong H; Mulders PF; van Oort IM; Schalken JA
    Prostate; 2014 Sep; 74(12):1222-30. PubMed ID: 25043536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
    Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
    Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.